Tailored Preclinical Research Service for Pseudocowpox Virus Therapeutic & Diagnostic Development

Overview

Pseudocowpox Virus (PCPV) belongs to the Poxviridae family with a linear double-stranded DNA genome of 145 kb. The genome features 134 open reading frames (ORFs) and is split into central and terminal sections. The central region produces structural proteins and replication factors, while terminal regions contain virulence elements that control disease-causing capacity. PCPV mainly affects dairy cows, which develop contagious eczema with skin lesions on their teats and udders. The virus spreads worldwide via cattle transportation and has zoonotic characteristics, which enable it to infect humans. The virus manifests as localized skin lesions on infected humans when exposure occurs through cuts or abrasions. Creative Biolabs delivers all-encompassing preclinical research services for viral research through viral vector construction, animal model development, and assessment of virus infection and immune response. Our specialized solutions help speed the development process for antiviral drugs and vaccines as well as immunotherapies.

Accelerated PCPV Preclinical Research Services (Therapeutics & Diagnostics)

• For Therapeutics Development

In Vitro Antiviral Efficacy Assays

• MTT Assay, LDH Assay, or Cell Viability Assays: The purpose of these assays is to determine the cytotoxic effects that potential antiviral substances have on host cells.
• Plaque Reduction Assay: Researchers use the Plaque Reduction Assay to measure how well antiviral compounds stop viral replication.
• Virus Yield Reduction Assay: This assay evaluates how well a compound can decrease the concentration of viruses.
• Viral Antigen Detection: The assay measures PCPV antigen expression in infected cells using fluorescently marked antibodies.
• Indirect Immunofluorescence: This technique identifies specific viral proteins through primary antibody binding followed by secondary antibodies that carry a fluorescent tag.

In Vivo Efficacy Studies (Animal Models)

• Viral Load Measurement: Scientists measure viral load within tissues like skin lesions, blood, or internal organs by employing PCR or viral titer assays. Antiviral effectiveness becomes apparent when treatment results in decreased viral load.
• Lesion Size and Healing Time: Researchers evaluate infection severity by monitoring the size and quantity of skin lesions on infected animals. The effectiveness of therapy is established by evaluating treatment's ability to lessen lesion development or speed up the healing process.
• PK Studies: Researchers use these studies to analyze how the therapeutic agent moves through distribution, absorption, metabolism, and excretion (ADME) in animal models. Researchers take blood, tissue, and urine samples from animals at different times after treatment to analyze drug levels and study their in vivo activity.

• For Diagnostics Development

Antigen Detection Assays

• Antigen-Based ELISA: The assay enables viral antigen detection (specific viral proteins) from clinical specimens, including skin lesions and blood samples.
• Viral Antigen Detection: The test uses antibodies labeled with fluorescent markers to attach to viral antigens produced by infected cells.
• Rapid Diagnostic Test (RDT): This point-of-care test detects viral antigens present in clinical specimens, including skin lesion samples and nasal swabs.

Nucleic Acid Detection Assays

• Real-Time PCR (qPCR): Quantifying viral DNA in clinical samples relies most heavily on this methodology. The qPCR technique targets distinct portions of the PCPV genome, such as genes A26L or B2L, to quantify viral concentrations in biological samples, including tissues and fluids like blood or nasal swabs.
• RT-PCR: The DNA virus PCPV can be analyzed with RT-PCR to identify its RNA transcripts when viral replication or transcription is active.
• Whole Genome Sequencing (WGS): NGS provides whole genome sequencing capabilities for PCPV that prove essential for epidemiological studies and precise virus strain identification.

Antibody Detection Assays (Serology)

• IgM and IgG ELISA: The assays allow detection of IgM antibodies, which emerge early during the infection's acute phase, and IgG antibodies, which develop following previous infections or viral exposure.
• Antibody Detection: The detection method can be used to identify specific antibodies that target PCPV proteins within animal serum samples.
• IFA for Antibody Detection: The assay detects IgM and IgG antibodies within animal serum samples.

Request a Quote

Products for PCPV Research

The production of recombinant proteins involves the introduction of the PCPV genome genes into host cells, which subsequently produce these proteins abundantly. The use of monoclonal antibodies (mAbs) against PCPV plays a vital role in diagnostics as well as therapeutic applications and helps scientists understand how the virus evades the immune system.

• Recombinant PCPV proteins or antigens

• Antibodies against PCPV proteins

Get a Quote Today

Applications

1. During vaccine research, scientists utilize PCPV as a living vector for gene transfer and as an agent to fight other animal viruses.

2. Biotechnology research uses this method for gene delivery and as a possible biocontrol solution.

3. Scientists can use the virus to create diagnostic tools that differentiate it from other skin disorders.

4. PCPV research helps to understand viral pathogenesis and develop cross-protective vaccines usable in veterinary and human medical fields.

Advantages

1. In Vitro & In Vivo Capabilities: Our research methods include cell culture-based assays and animal models, which together enable thorough evaluations of viral therapeutics.

2. Accelerated Timelines: Our research processes enhance drug discovery speed, which leads to faster development of therapeutic candidates.

3. Regulatory Compliance: Global GLP and GxP standards guide our research studies to maintain compliance and support clinical development.

4. Collaborative Approach: Clients receive continuous support and project updates throughout research activities to reach targeted goals.

FAQs